<DOC>
	<DOCNO>NCT00915629</DOCNO>
	<brief_summary>Vulvovaginal candidiasis ( VVC ) common infection among woman associate considerable morbidity health-care cost . 75 % woman suffer Candida infection least one time life . 20 % woman suffer VVC ≥ 4 episode VVC one year prior survey . 80 % VVC cause Candida albicans . Current treatment , base imidazole , face many failure recurrence . The type probiotic Lactobacillus may participate prevention recurrent vulvo-vaginitis reduce proliferation intestinal Candida albicans , adherence vaginal wall , potentiation propagation . The primary objective study investigate supplementary treatment could improve initial cure rate vaginal econazole therapy .</brief_summary>
	<brief_title>Prevention Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<criteria>woman 1865 year suffer 4 episode VVC 1 year prior survey participant must symptomatic microbiological proof infection candida albicans Pregnancy , lactation HIV infection , chemotherapy illness serious enough induce immune deficiency . A diabetic patient systematically exclude ; Vulvovaginitis / cervicitis specific , define bacteriological examination presence herpes virus , gonorrhea chlamydia ; Bacterial Vaginosis Trichomonas ; Use vaginal probiotic month inclusion ; Cure probiotic month precede inclusion ; Contraindication Gynopévaryl LP</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>